14 completed, 2 unknown. 9 Phase 2, 4 Phase 1, 3 Not applicable, 2 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 9 |
| Phase 1 | 4 | Completed 4 |
| Not applicable | 3 | Unknown 2, Completed 1 |
| Early Phase 1 | 2 | Completed 2 |
Follow resiquimod: new trials by email Literature Review of resiquimod trials Research Report on resiquimod
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lung Immune Challenge Study: Controlled Exposure to Inhaled Resiquimod (R848) R848, Saline - Innate Immunity, Mucosal Immunity | Not applicable | Unknown | Akhilesh Jha | 36 | 2024-05-24 | 2024-07-10 |
| Nasal Immune Challenge Study R848, Saline - Innate Inflammatory Response, Asthma | Not applicable | Unknown | Cambridge University Hospitals NHS Foundation Trust | 24 | 2022-08-09 | 2023-09-01 |
| Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists Peptide Vaccine (LPV7) + Tetanus peptide, PolyICLC, Resiquimod - Melanoma, Metastatic Melanoma | Phase 1 / Phase 2 | Completed | Craig L Slingluff, Jr | 50 | 2014-05-01 | 2024-02-28 |
| Development of Human Nasal Challenge Models With Microbial Constituents and Grass Pollen Poly ICLC, Poly I:C, R848 - Allergic Rhinitis, Asthma | Not applicable | Completed | Imperial College London | 93 | 2014-03-01 | 2021-11-05 |
| Enhancing Influenza Vaccination in Seniors With TLR (Toll Like Receptor) Agonists resiquimod, placebo gel - Influenza Vaccination in Seniors | Phase 1 | Completed | University of British Columbia | 59 | 2013-04-01 | 2013-08-28 |
| Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery Montanide ISA 51 VG, MART-1 antigen, laboratory biomarker analysis - Recurrent Melanoma, Stage IIA Melanoma | Early Phase 1 | Completed | Mayo Clinic | 30 | 2012-10-01 | 2018-10-09 |
| Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist gp100, R848 gel, MAGE-3 - Melanoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 47 | 2010-05-20 | 2021-08-13 |
| A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1 CDX-1401 in combination with Resiquimod and/or Poly-ICLC, CDX-1401, Resiquimod - Advanced Malignancies | Phase 1 / Phase 2 | Completed | Celldex Therapeutics | 70 | 2009-09-01 | 2016-06-27 |
| Randomized, Double Blind, Placebo-controlled Topical Resiquimod Adjuvant for NY-ESO-1 Protein Vaccination NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod, NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod/placebo - Tumors | Phase 1 | Completed | Nina Bhardwaj | 26 | 2009-02-01 | 2015-01-08 |
| Vaccine Therapy and Resiquimod in Treating Patients With Stage II, Stage III, or Stage IV Melanoma That Has Been Completely Removed by Surgery resiquimod - Melanoma (Skin) | Early Phase 1 | Completed | Mayo Clinic | 30 | 2006-04-01 | 2014-10-31 |
| Four Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects Resiquimod - Warts | Phase 2 | Completed | Graceway Pharmaceuticals, LLC | 84 | 2005-03-01 | 2007-02-19 |
| An up to Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects Resiquimod - Warts | Phase 2 | Completed | Graceway Pharmaceuticals, LLC | 84 | 2005-03-01 | 2007-02-19 |
| Study With a Topical Gel to Treat Common Warts in Adults Resiquimod - Warts | Phase 2 | Completed | Graceway Pharmaceuticals, LLC | 48 | 2004-10-01 | 2007-02-19 |
| Study With a Topical Gel to Treat Common Warts in Adults Resiquimod - Warts | Phase 2 | Completed | Graceway Pharmaceuticals, LLC | 88 | 2004-08-01 | 2007-02-19 |
| Four Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Adults Resiquimod - Warts | Phase 2 | Completed | Graceway Pharmaceuticals, LLC | 88 | 2004-04-01 | 2007-02-19 |
| Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Adults Resiquimod - Warts | Phase 2 | Completed | Graceway Pharmaceuticals, LLC | 88 | 2004-03-01 | 2007-02-19 |
Warts (6) · Melanoma (5) · Asthma (3) · Neoplasms (3) · Inflammation (2) · Virus Diseases (2) · Adenocarcinoma (1) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Chondrosarcoma (1) · Esophageal Neoplasms (1) · Hypersensitivity (1) · Influenza, Human (1) · Latent Tuberculosis (1) · Neoplasm Metastasis (1)
Graceway Pharmaceuticals, LLC (6) · Mayo Clinic (2) · Akhilesh Jha (1) · Cambridge University Hospitals NHS Foundation Trust (1) · Celldex Therapeutics (1) · Craig L Slingluff, Jr (1) · Imperial College London (1) · M.D. Anderson Cancer Center (1) · Nina Bhardwaj (1) · University of British Columbia (1)
United States (11) · United Kingdom (3) · Canada (1)
Craig L Slingluff, Jr., M.D. (1) · Jan P Dutz, MD (1) · Michael A. Davies, PHD (1) · Nina Bhardwaj, MD, PhD (1) · Peter JM Openshaw, FRCP, PhD, FRSB, FMedSci (1) · Rachel Sabado, PhD (1) · Robin Shattock, PhD (1) · Svetomir Markovic, M.D., Ph.D. (1) · Svetomir Markovic, MD, PhD (1) · Trevor Hansel, FRCPath, PhD (1)
P30CA015083 (1)